Ubrogepant Clinical Trials (2026): 16 Studies for Migraine & Migraine, With or Without Aura
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
16 Ubrogepant clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 7 indications (including Migraine & Migraine, With or Without Aura) and 8,673 total planned enrollment. 7 Phase 3 Ubrogepant trials, 3 Phase 4 are listed. 3 Ubrogepant clinical trials are actively recruiting at 85 U.S. sites across 32 states. Most recent activity: NCT05127954 (Jan 2028).
Where to Participate: All Ubrogepant Trial Sites in the U.S. (85 sites across 32 states)
Every actively recruiting Ubrogepanttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Rehabilitation & Neurological Services /ID# 229969 | Huntsville35805-4046 | NCT05125302 | Map |
| AL | The Center for Clinical Trials - Saraland /ID# 231546 | Saraland36571 | NCT05125302 | Map |
| AZ | Velocity Clinical Research - Phoenix /ID# 274478 | Phoenix85006 | NCT05125302 | Map |
| AR | HealthStar Research Glenwood /ID# 275303 | Glenwood71943 | NCT05125302 | Map |
| AR | HealthStar Research of Hot Springs /ID# 273256 | Hot Springs71913 | NCT05125302 | Map |
| AR | Preferred Research Partners /ID# 230725 | Little Rock72211 | NCT05125302 | Map |
| CA | Advanced Research Center /ID# 227962 | Anaheim92805 | NCT05125302 | Map |
| CA | Neuro Pain Research Center /ID# 227966 | Fresno93710 | NCT05125302 | Map |
| CA | Alliance for Research Alliance for Wellness /ID# 230546 | Long Beach90807 | NCT05125302 | Map |
| CA | Excell Research, Inc /ID# 230899 | Oceanside92056 | NCT05125302 | Map |
| CA | Paradigm Clinical Research - San Diego /ID# 269608 | San Diego92108-1681 | NCT05125302 | Map |
| CA | Lumos Clinical Research Center /ID# 231267 | San Jose95124-4108 | NCT05125302 | Map |
| CA | Sunwise Clinical Research /ID# 230971 | Walnut Creek94596 | NCT05125302 | Map |
| CA | Amicis Research Center /ID# 272621 | Winnetka91306 | NCT05125302 | Map |
| CO | Children's Hospital Colorado - Aurora /ID# 231879 | Aurora80045 | NCT05125302 | Map |
| CT | New England Institute for Clinical Research /ID# 230635 | Stamford06905 | NCT05125302 | Map |
| DC | Emerson Clinical Research Institute - Connecticut Avenue - Washington /ID# 231693 | Washington D.C.20009 | NCT05125302 | Map |
| FL | Encore Medical Research of Boynton Beach LLC /ID# 246833 | Boynton Beach33436-7245 | NCT05125302 | Map |
| FL | Gulf Coast Clinical Research Center /ID# 230020 | Fort Myers33912 | NCT05125302 | Map |
| FL | AGA Clinical Trials /ID# 230554 | Hialeah33012 | NCT05125302 | Map |
| FL | Encore Medical Research /ID# 245682 | Hollywood33021 | NCT05125302 | Map |
| FL | Columbus Clinical Services, Llc /Id# 230880 | Miami33125 | NCT05125302 | Map |
| FL | My Preferred Research LLC /ID# 227886 | Miami33155 | NCT05125302 | Map |
| FL | Medical Research Group of Central Florida /ID# 231632 | Orange City32763 | NCT05125302 | Map |
| FL | Clinical Associates of Orlando, LLC /ID# 272619 | Orlando32819 | NCT05125302 | Map |
| FL | FWD Clinical Research - Spring Hill /ID# 229815 | Spring Hill34609-5692 | NCT05125302 | Map |
| FL | University of South Florida- Neuroscience Institute /ID# 229324 | Tampa33613 | NCT05125302 | Map |
| FL | Encore Medical Research - Weston /ID# 246809 | Weston33331 | NCT05125302 | Map |
| FL | Pediatric Neurology and Epilepsy Specialists /ID# 229967 | Winter Park32789-7111 | NCT05125302 | Map |
| GA | Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 231134 | Atlanta30328 | NCT05125302 | Map |
| GA | Rare Disease Research /ID# 231046 | Atlanta30318-2512 | NCT05125302 | Map |
| GA | Coastal Georgia Child Neurology /ID# 231409 | Brunswick31520-1601 | NCT05125302 | Map |
| GA | CenExcel iResearch LLC /ID# 227903 | Decatur30030 | NCT05125302 | Map |
| GA | Velocity Clinical Research - Savannah. /ID# 228992 | Savannah31406 | NCT05125302 | Map |
| ID | Velocity Clinical Research - Boise /ID# 231871 | Meridian83642 | NCT05125302 | Map |
| IL | Chicago Headache Center & Research Institute /ID# 248625 | Chicago60657 | NCT05125302 | Map |
| IL | Ascension Saint Alexius /ID# 275261 | Hoffman Estates60169 | NCT05125302 | Map |
| IA | Accellacare - McFarland Clinic /ID# 229789 | Ames50010 | NCT05125302 | Map |
| KS | Clinical Associates Midwest, LLC /ID# 274315 | Overland Park66214 | NCT05125302 | Map |
| KS | Alliance For Multispeciality Research - Wichita East /ID# 234126 | Wichita67207 | NCT05125302 | Map |
| KY | University of Kentucky Chandler Medical Center /ID# 230827 | Lexington40536 | NCT05125302 | Map |
| MD | Pharmasite Research, Inc. /ID# 227908 | Baltimore21208 | NCT05125302 | Map |
| MN | Minneapolis Clinic of Neurology - Burnsville /ID# 232551 | Burnsville55337-6732 | NCT05125302 | Map |
| MS | Proven Endpoints LLC /ID# 239513 | Ridgeland39157 | NCT05125302 | Map |
| NE | Cognitive Clinical Trials (CCT) - Papillion /ID# 232552 | Papillion68046-4131 | NCT05125302 | Map |
| NH | Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 230312 | Nashua03060-3483 | NCT05125302 | Map |
| NJ | Goryeb Childrens Hospital /ID# 229507 | Morristown07960 | NCT05125302 | Map |
| NY | Dent Neurologic Institute - Amherst /ID# 231182 | Amherst14226 | NCT05125302 | Map |
| NY | SUNY Upstate Medical University /ID# 239898 | Syracuse13210 | NCT05125302 | Map |
| OH | Cincinnati Childrens Hospital Medical Center /ID# 244689 | Cincinnati45229 | NCT05125302 | Map |
| OH | Headache Center of Hope /ID# 242645 | Cincinnati45236-1875 | NCT05125302 | Map |
| OH | Patient Priority Clinical Sites, LLC /ID# 238485 | Cincinnati45215-2123 | NCT05125302 | Map |
| OH | University Of Cincinnati Medical Center /ID# 231199 | Cincinnati45219 | NCT05125302 | Map |
| OH | Centricity Research Columbus /ID# 231181 | Columbus43213 | NCT05125302 | Map |
| OH | CincyScience /ID# 230046 | West Chester45069 | NCT05125302 | Map |
| OR | Providence Brain and Spine Institute /ID# 231607 | Portland97225-6625 | NCT05125302 | Map |
| PA | Children's Hospital of Philadelphia - Main /ID# 232487 | Philadelphia19104-4319 | NCT05125302 | Map |
| PA | Frontier Clinical Research - Scottdale /ID# 231913 | Scottdale15683 | NCT05125302 | Map |
| PA | Frontier Clinical Research - Smithfield /ID# 231912 | Smithfield15478 | NCT05125302 | Map |
| SC | Tribe Clinical Research LLC /ID# 230422 | Greenville29607-4021 | NCT05125302 | Map |
| TN | Access Clinical Trials, Inc. /ID# 228002 | Nashville37203 | NCT05125302 | Map |
| TX | Austin Regional Clinic - ARC Four Points /ID# 276301 | Austin78726 | NCT05125302 | Map |
| TX | UT Health Austin at Dell Children's Neurology Clinic /ID# 244266 | Austin78723-3079 | NCT05125302 | Map |
| TX | Velocity Clinical Research, Austin /ID# 230557 | Austin78759 | NCT05125302 | Map |
| TX | Tekton Research - Beaumont /ID# 231207 | Beaumont77706-3067 | NCT05125302 | Map |
| TX | Cedar Health Research /ID# 228003 | Dallas75251-2202 | NCT05125302 | Map |
| TX | Relaro Medical Trials /ID# 239642 | Dallas75243 | NCT05125302 | Map |
| TX | Epic Medical Research - DeSoto /ID# 274314 | DeSoto75115 | NCT05125302 | Map |
| TX | Innovare Research Group, LLC /ID# 277617 | Friendswood77546 | NCT05125302 | Map |
| TX | Aavon Clinical Trials /ID# 279007 | Houston77074 | NCT05125302 | Map |
| TX | DM Clinical Research /ID# 229826 | Houston77065 | NCT05125302 | Map |
| TX | Houston Clinical Research Associates /ID# 244889 | Houston77090-2633 | NCT05125302 | Map |
| TX | Pioneer Research Solutions - Houston - Stancliff Road /ID# 274316 | Houston77099 | NCT05125302 | Map |
| TX | Sante Clinical Research /ID# 246503 | Kerrville78028-9640 | NCT05125302 | Map |
| TX | FMC Science /ID# 231915 | Lampasas76550 | NCT05125302 | Map |
| TX | Livingspring Family Medical Center /ID# 249869 | Mansfield76063-5622 | NCT05125302 | Map |
| TX | Road Runner Research /ID# 230527 | San Antonio78249-3538 | NCT05125302 | Map |
| TX | ClinPoint Trials /ID# 230295 | Waxahachie75165-1430 | NCT05125302 | Map |
| UT | Pantheon Clinical Research /ID# 250703 | Bountiful84010-4968 | NCT05125302 | Map |
| UT | Highland Clinical Research /ID# 239362 | Salt Lake City84124 | NCT05125302 | Map |
| VA | Children's Hospital of The King's Daughters - Children's Medical Tower /ID# 230581 | Norfolk23507-1901 | NCT05125302 | Map |
| WA | Core Clinical Research /ID# 227904 | Everett98201 | NCT05125302 | Map |
| WA | MultiCare Institute for Research and Innovation /ID# 231061 | Tacoma98405 | NCT05125302 | Map |
| WV | Frontier Clinical Research - Kingwood /ID# 231914 | Kingwood26537-9797 | NCT05125302 | Map |
| WI | Mind+ Neurology /ID# 275529 | Mequon53092 | NCT05125302 | Map |
Ubrogepant clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | Total |
|---|---|---|---|---|---|---|
| P1 | 4 | 4 | ||||
| P3 | 1 | 1 | 1 | 4 | 7 | |
| P4 | 1 | 1 | 1 | 3 | ||
| N/A | 1 | 1 | 2 |
Recruiting Ubrogepant clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05127954 | UBRO PEDS OLELong-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) | P3 | Migraine | 1,200 | Jan 2022 |
| NCT05125302 | Ubro PedsStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | P3 | Migraine | 1,059 | Jan 2022 |
| NCT06212661 | Migraine Medication Effects on Urinary Symptoms | — | Overactive Bladder | 200 | Apr 2024 |
Ubrogepant clinical trials by indication
Migraine (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05127954 | UBRO PEDS OLE | P3 | enrolling by invitation | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) |
| NCT06417775 | UBRO MM | P3 | active not recruiting | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
| NCT05125302 | Ubro Peds | P3 | recruiting | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) |
| NCT06578585 | — | P1 | completed | A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine |
| NCT05654298 | — | N/A | completed | Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin |
| NCT04492020 | UBR Prodrome | P3 | completed | Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants |
| NCT04818515 | — | P1 | completed | Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine |
| NCT04179474 | — | P1 | completed | Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine |
Migraine, With or Without Aura (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02873221 | — | P3 | completed | An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine |
| NCT02867709 | ACHIEVE II | P3 | completed | Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine |
| NCT02828020 | ACHIEVE I | P3 | completed | Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine |
Overactive Bladder (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06212661 | — | N/A | enrolling by invitation | Migraine Medication Effects on Urinary Symptoms |
Healthy Volunteers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05892757 | — | P1 | completed | Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers |
Headache, Migraine (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05503082 | UNION | P4 | active not recruiting | Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies |
Migraine With Aura (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05214001 | ATOM | P4 | terminated | Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine |
Episodic Migraine (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05264129 | TANDEM | P4 | completed | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine |
Ubrogepant pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| UNION | NCT05503082 | P4 | active not recruiting | Headache, Migraine | 164 | PMID 32073660 |
| ATOM | NCT05214001 | P4 | terminated | Migraine With Aura | 8 | — |
| TANDEM | NCT05264129 | P4 | completed | Episodic Migraine | 263 | PMID 39569702 |
| UBRO PEDS OLE | NCT05127954 | P3 | enrolling by invitation | Migraine | 1,200 | — |
| UBRO MM | NCT06417775 | P3 | active not recruiting | Migraine | 496 | — |
| Ubro Peds | NCT05125302 | P3 | recruiting | Migraine | 1,059 | — |
| UBR Prodrome | NCT04492020 | P3 | completed | Migraine | 518 | PMID 39399572 |
| ACHIEVE II | NCT02867709 | P3 | completed | Migraine, With or Without Aura | 1,686 | PMID 35468729 |
| ACHIEVE I | NCT02828020 | P3 | completed | Migraine, With or Without Aura | 1,672 | PMID 36125279 |
Terminated and withdrawn Ubrogepant trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05214001terminatedEvaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
All Ubrogepant trials (16)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05127954 | UBRO PEDS OLE | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17) | P3 | enrolling by invitation | 1,200 | AbbVie | Jan 2022 |
| NCT06417775 | UBRO MM | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | P3 | active not recruiting | 496 | AbbVie | Sep 2024 |
| NCT05125302 | Ubro Peds | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | P3 | recruiting | 1,059 | AbbVie | Jan 2022 |
| NCT06212661 | Migraine Medication Effects on Urinary Symptoms | — | enrolling by invitation | 200 | The Cleveland Clinic | Apr 2024 | |
| NCT06578585 | A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine | P1 | completed | 43 | H. Lundbeck A/S | Sep 2024 | |
| NCT05503082 | UNION | Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies | P4 | active not recruiting | 164 | Chicago Headache Center & Research Institute | Sep 2022 |
| NCT05214001 | ATOM | Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine | P4 | terminated | 8 | Messoud Ashina, MD | Jun 2022 |
| NCT05892757 | Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers | P1 | completed | 24 | AbbVie | Jul 2023 | |
| NCT05264129 | TANDEM | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine | P4 | completed | 263 | AbbVie | Mar 2022 |
| NCT05654298 | Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin | N/A | completed | 20 | Universitaire Ziekenhuizen KU Leuven | Mar 2022 | |
| NCT04492020 | UBR Prodrome | Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants | P3 | completed | 518 | AbbVie | Aug 2020 |
| NCT04818515 | Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine | P1 | completed | 26 | AbbVie | Mar 2021 | |
| NCT04179474 | Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine | P1 | completed | 40 | Allergan | Sep 2019 | |
| NCT02873221 | An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine | P3 | completed | 1,254 | Allergan | Sep 2016 | |
| NCT02867709 | ACHIEVE II | Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine | P3 | completed | 1,686 | Allergan | Aug 2016 |
| NCT02828020 | ACHIEVE I | Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine | P3 | completed | 1,672 | Allergan | Jul 2016 |
Ubrogepant clinical trials: frequently asked questions
- How many Ubrogepant clinical trials are there?
- 16 Ubrogepant clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 10 are marked completed.
- Are Ubrogepant clinical trials recruiting in 2026?
- Yes — 3 Ubrogepant trials are actively recruiting in 2026, with 85 U.S. sites across 32 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ubrogepant being studied for?
- Ubrogepant is being studied for Migraine, Migraine, With or Without Aura, Headache, Migraine, Healthy Volunteers, Interstitial Cystitis and 8 more. The trials are grouped by indication on this page.
- What phase is Ubrogepant in?
- Ubrogepant clinical trials span 3 Phase 4, 7 Phase 3, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ubrogepant clinical trials?
- The lead sponsor across the most Ubrogepant trials is AbbVie, with 6 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ubrogepantas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: